Navigation Links
3-Drug Combo Reduces Nausea After Chemo
Date:5/11/2009

Study finds adding casopitant mesylate to regimen cuts side effects

MONDAY, May 11 (HealthDay News) -- The addition of the drug casopitant mesylate (CM) to the conventional two-drug regimen of dexamethasone and ondansetron greatly reduces chemotherapy-induced nausea and vomiting (CINV) in patients undergoing highly emetogenic chemotherapy (HEC), a new study concludes.

HEC is used to treat many types of solid tumor cancers, including colorectal and pancreatic cancer. Drugs such as dexamethasone and ondansetron are effective in reducing CINV in the first 24 hours after chemotherapy but only provide moderate relief during the delayed phase (24 to 120 hours after chemotherapy).

The phase 3 study included 810 patients who were receiving dexamethasone and ondansetron after undergoing HEC. They were randomly selected to also receive either a placebo (269 patients), a single 150-milligram oral dose of CM (271), or three-day intravenous plus oral CM (90-mg intravenous on the first day plus 50-mg oral on the second and third days).

The study found that 86 percent of patients in the single oral CM group and 80 percent of those in the intravenous plus oral CM group achieved a complete response (no vomiting, retching or use of rescue medications) for the first 120 hours after their first cycle of HEC treatment, compared with 66 percent of patients in the placebo group.

"A three-drug regimen including a single oral dose or three-day intravenous plus oral regimen of casopitant mesylate plus dexamethasone and ondansetron significantly reduced CINV events in patients receiving HEC compared with a two-drug regimen of dexamethasone and ondansetron," wrote Steven Grunberg, a professor at the University of Vermont, Burlington, and colleagues.

The study appears online and in the June print edition of The Lancet Oncology.

More information

The U.S. National Cancer Institute has more about managing chemotherapy-related nausea and vomiting.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, May 10, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. 3-drug combination extremely promising as first-line therapy for multiple myeloma
2. 3-Drug Combo Improves Advanced Pancreatic Cancer Outcomes
3. 3-drug chemotherapy combination increases organ preservation in patients with larynx cancer
4. Radiation and drug combo helps boost efficacy of lung cancer treatment
5. Aerobic, Weight Training Combo Best Against Diabetes
6. New antibiotic drug combo to speed up treatment of tuberculosis
7. Drug Combo Helps Fight Marfan Syndrome
8. Drug Combo Blocks Pain Without Impairing Movement
9. Two-Drug Combo Fights Brain Tumors
10. CPR, Defibrillator Combo Boosts Cardiac Incident Survival
11. Drug Combo Boosts Multiple Myeloma Survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
3-Drug Combo Reduces Nausea After Chemo
(Date:10/13/2017)... ... 13, 2017 , ... “The Journey: From the Mountains to the Mission Field”: ... souls in the Philippines. “The Journey: From the Mountains to the Mission Field” is ... Bible. She has taught all ages and currently teaches a class of ladies at ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of ... innovative new design of the shoulder pad. The shoulder pad provides optimal support ... your pain while using cold therapy. By utilizing ice and water that is circulated ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Leading pediatric oncology ... in Washington, D.C., for the 49th Congress of the International Society of Paediatric ... President of the Center for Cancer and Blood Disorders at Children’s National, ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") ... Surgical facility in Las Piedras, Puerto Rico ... and blades. ... the facility sustained minor structural damage, temporary loss of ... Repairs have been completed, manufacturing operations have resumed, and ...
Breaking Medicine Technology: